Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32511981

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jul
First author
Blay JY

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jul;21(7):864-865. doi: 10.1016/S1470-2045(20)30209-6.
    note
    Source null
    related pmid
    32511982
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Jul;21(7):e341. doi: 10.1016/S1470-2045(20)30353-3.
    note
    Source null
    related pmid
    32615117
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2020 Sep;21(9):e414. doi: 10.1016/S1470-2045(20)30438-1.
    note
    Source null
    related pmid
    32888464
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Sep;21(9):e415. doi: 10.1016/S1470-2045(20)30479-4.
    note
    Source null
    related pmid
    32888465
    relationship
    Comment in
  5. citation
    Future Oncol. 2021 Dec 1;17(36):5007-5012. doi: 10.2217/fon-2021-0803.
    note
    Source null
    related pmid
    34661454
    relationship
    Comment in

Authors and identifiers

  1. name
    Blay JY
    type
    Author
  2. name
    Serrano C
    type
    Author
  3. name
    Heinrich MC
    type
    Author
  4. name
    Zalcberg J
    type
    Author
  5. name
    Bauer S
    type
    Author
  6. name
    Gelderblom H
    type
    Author
  7. name
    Schöffski P
    type
    Author
  8. name
    Jones RL
    type
    Author
  9. name
    Attia S
    type
    Author
  10. name
    D'Amato G
    type
    Author
  11. name
    Chi P
    type
    Author
  12. name
    Reichardt P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Blay JY
    type
    Author
  2. name
    Serrano C
    type
    Author
  3. name
    Heinrich MC
    type
    Author
  4. name
    Zalcberg J
    type
    Author
  5. name
    Bauer S
    type
    Author
  6. name
    Gelderblom H
    type
    Author
  7. name
    Schöffski P
    type
    Author
  8. name
    Jones RL
    type
    Author
  9. name
    Attia S
    type
    Author
  10. name
    D'Amato G
    type
    Author
  11. name
    Chi P
    type
    Author
  12. name
    Reichardt P
    type
    Author
bibliography ids
  1. nci-bib-875a157ce9d9624ec922ea26
book metadata
content sha256
ddfd28f657801cf34bddbb43b3ba18528fa916870bbae40e7df4fed0973a8965
document type
citation
dois
  1. 10.1016/S1470-2045(20)30168-6
electronic publication date
display
2020 Jun 5
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32511981
immutable id
pubmed:32511981@ddfd28f657801cf34bddbb43b3ba18528fa916870bbae40e7df4fed0973a8965
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
923-934
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jul;21(7):864-865. doi: 10.1016/S1470-2045(20)30209-6.
    note
    Source null
    related pmid
    32511982
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Jul;21(7):e341. doi: 10.1016/S1470-2045(20)30353-3.
    note
    Source null
    related pmid
    32615117
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2020 Sep;21(9):e414. doi: 10.1016/S1470-2045(20)30438-1.
    note
    Source null
    related pmid
    32888464
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Sep;21(9):e415. doi: 10.1016/S1470-2045(20)30479-4.
    note
    Source null
    related pmid
    32888465
    relationship
    Comment in
  5. citation
    Future Oncol. 2021 Dec 1;17(36):5007-5012. doi: 10.2217/fon-2021-0803.
    note
    Source null
    related pmid
    34661454
    relationship
    Comment in
outcomes validated
false
pmid
32511981
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
e5ded7469585bfcde8fa67868815dcb4fd5ed1b73cc7b047f647d0d6a72f4c6c
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Jul
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32511981/
title
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice